Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Study of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Advanced Cancers
2015-000402-19Phase 2Terminated
- Sponsor
- TC BioPharm
- Start
- May 2015
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of immunicell in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more, sponsored by TC BioPharm. Primary endpoint: Stage 1 primary endpoint. Started May 2015; status: terminated.
02
Drugs
immunicell
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)cancer
Beyond the preview
Go deeper on 2015-000402-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000402-19.